When was Horizon Therapeutics founded?

Horizon Therapeutics was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Horizon Therapeutics located?

Horizon Therapeutics is headquartered in Dublin, Ireland. It is registered at Lake Forest, Illinois.

How many employees does Horizon Therapeutics have?

As of May 31, 2026, the latest employee count at Horizon Therapeutics is 2716.

Is Horizon Therapeutics a funded company?

Horizon Therapeutics is a funded company, having raised a total of $61.8M across 7 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Oct 28, 2008.

When was the latest funding round of Horizon Therapeutics?

Horizon Therapeutics' latest funding was a $***** Post IPO round on Oct 2014, with participation from 0 investor.

What is the annual revenue of Horizon Therapeutics?

Annual revenue of Horizon Therapeutics is between $500M and $1B as on Dec 31, 2022

Where does Horizon Therapeutics rank among its competitors?

Horizon Therapeutics ranks 28th amongst 659 active competitors, of which 213 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Horizon Therapeutics?

Horizon Therapeutics' top competitors include BridgeBio, Alnylam and Alexion. Among them, BridgeBio secured the most recent funding round in April, 2024.

Horizon Therapeutics - 2026 Company Profile, Funding, Competitors & Financials

Horizon Therapeutics is an acquired company based in Dublin (Ireland), founded in 2008. It operates as a Developer of drugs for treating rare and autoimmune diseases. Horizon Therapeutics has raised $61.8M in funding. The company has 659 active competitors, including 213 funded and 183 that have exited. Its top competitors include companies like BridgeBio, Alnylam and Alexion.

Company Details

Developer of drugs for treating rare and autoimmune diseases. The lead candidates of the company are UPLIZNA fucosylated IgG 1 kappa (IgG1κ) monoclonal antibodies for myasthenia gravis, HZN-825 for idiopathic pulmonary fibrosis, and HZN-4920 for focal segmental glomerulosclerosis as well as kidney transplant rejection, rheumatoid arthritis, and Sjogren’s syndrome.

Website: horizontherapeutics.com
Social
Email ID: *****@horizontherapeutics.com
Phone Number: +353 **********
Registered Address: Lake Forest, Illinois

Key Metrics

Founded Year

2008

Location

Dublin, Ireland

Stage

Acquired

Total Funding

$61.8M in 7 rounds

Latest Funding Round

Post IPO, Oct 2014, $*****

Investors

Quaker Partners Management & 5 more

Ranked

28^th among 659 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2022

Employee Count

2,716 as on May 31, 2026

Investment & Acquisitions

Raptor Pharma & 2 more

Similar Companies

BridgeBio & 744 more

Exit Details

Acquired by Amgen (Dec 12, 2022)

View Horizon Therapeutics' full profile

Horizon Therapeutics is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
HORIZON PHARMA USA, INC. CIN: 562523161 , United States, Active	Dec 31, 1999	-	1877 (As on Dec 31, 2023)	-
HORIZON THERAPEUTICS NORWAY AS CIN: 929107209 , Norway, Active	Mar 29, 2022	-	-
HORIZON PHARMA, INC. CIN: 272179987 , United States, Active	Dec 31, 1999	-	934 (As on Dec 31, 2017)	-
HORIZON PHARMA PLC CIN: 1492426 , United States, Active	Mar 22, 2010	$500M - $1B (As on Dec 31, 2022)	-	-

Horizon Therapeutics got acquired by Amgen on Dec 12, 2022.

Click here to take a look at Horizon Therapeutics's acquisition in detail

Horizon Therapeutics has raised a total funding of $61.8M over 7 rounds. Its first funding round was on Oct 28, 2008. Horizon Therapeutics has 6 institutional investors.

Here is the list of recent funding rounds of Horizon Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 2014	9115708	Post IPO	3254865	6623859	9858520	5416373
Nov 19, 2013	1375431	Post IPO	8220816	7501673	3787420	1713414
Mar 16, 2012	5633071	Post IPO	8330654	7583589	8551956	6110468

Access funding benchmarks and valuations. Sign up today!

View details of Horizon Therapeutics's funding rounds and investors

Horizon Therapeutics' employee count trend

Horizon Therapeutics has 2,716 employees as of May 26. Here is Horizon Therapeutics's employee count trend over the years:

Employee count trend for Horizon Therapeutics

Uncover Horizon Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Horizon Therapeutics include BridgeBio, Alnylam and Alexion. Here is the list of Top 10 competitors of Horizon Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	74/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
8th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
9th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Flagship Pioneering, Arch Venture Partners ... & 6 others	70/100
10th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
28th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Quaker Partners Management, Athyrium Capital Management ... & 4 others	61/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Horizon Therapeutics's competitors? Click here to see the top ones

Horizon Therapeutics has acquired 3 companies including Raptor Pharma, Vidara Therapeutics and Nitec Pharma. Horizon Therapeutics has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Sep 12, 2016	Acquisition	Raptor Pharma	2005	Novato (United States)
Mar 19, 2014	Acquisition	Vidara Therapeutics	2011	Alpharetta (United States)
Apr 01, 2010	Acquisition	Nitec Pharma	2004	Reinach (Switzerland)